AbbVie (ABBV) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
AbbVie (ABBV) has outperformed Pfizer (PFE) over the past year, gaining 16.5% versus a gain of 6.6%. Over five years, ABBV leads with a +148.2% price change compared with -32.5% for PFE. AbbVie is the larger company by market cap ($479.52 billion vs $159.59 billion), about 3.0 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.7x vs 16.7x for AbbVie). Pfizer offers the higher dividend yield (6.14% vs 2.52%). Pfizer converts more of its revenue into profit, with a net margin of 12.4% versus 6.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | PFE |
|---|---|---|
| Share price | $271.36 | $28.00 |
| Market cap | $479.52B | $159.59B |
| 1-day change | +1.75% | +1.82% |
| YTD return | +18.76% | +12.45% |
| 1-year return | +16.55% | +6.59% |
| 5-year return | +148.20% | -32.51% |
| P/E ratio (TTM) | 76.66 | 36.84 |
| Forward P/E | 16.69 | 9.67 |
| EPS (TTM) | $3.54 | $0.76 |
| Dividend yield | 2.52% | 6.14% |
| Annual dividend | $6.83 | $1.72 |
| Revenue (latest FY) | $61.16B | $62.58B |
| Revenue growth (YoY) | +8.57% | -1.65% |
| Net income (latest FY) | $4.23B | $7.77B |
| Gross margin | 70.24% | 74.33% |
| Operating margin | 24.65% | — |
| Net margin | 6.91% | 12.42% |
| 52-week high | $274.94 | $29.21 |
| 52-week low | $190.75 | $23.62 |
| Distance from 52-week high | -1.30% | -4.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.48% | +3.25% |
| Average volume | 4.86M | 36.02M |
| Shares outstanding | 1.77B | 5.70B |
| Employees | 57,000 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AbbVie is about 3.0 times larger than Pfizer by market value ($479.52B vs $159.59B).
- AbbVie trades at a higher earnings multiple (76.7x vs 36.8x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.14% vs 2.52%).
- Pfizer is more profitable, keeping 12.4 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
- AbbVie grew revenue faster in its latest fiscal year (+8.57% vs -1.65%).
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
ABBV vs PFE FAQ
Which is bigger, AbbVie or Pfizer?
AbbVie (ABBV) is larger, with a market capitalization of $479.52B compared with $159.59B for Pfizer (PFE).
Which stock has performed better over the past year, ABBV or PFE?
ABBV returned +16.55% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or PFE?
PFE has the lower trailing P/E at 36.8, versus 76.7 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or Pfizer?
Pfizer has the higher yield at 6.14%, compared with 2.52% for AbbVie.
Are AbbVie and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.